FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Endpoint’s team competed in two seasons of the ESL Pro League (13 and 16), showing its skills against some pretty big ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

The integration also brings new CyberArk identity data into SentinelOne Singularity for AI SIEM and XDR use cases.

SentinelOne is making a major push this year around AI-powered SIEM, as well as cloud and data security, Channel Chief Brian ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

BlackBerry Limited BB has sold its Cylance endpoint security assets to Arctic Wolf. On Dec. 15, 2024, BlackBerry and Arctic Wolf, a global leader in security operations helping customers manage cyber ...

Action1, a leading provider of autonomous endpoint management solutions, today announced a major expansion of its free tier, ...

Learn the seven critical types of cybersecurity you need to know in 2025. Protect your data, prevent threats, and arm against cyber risks effectively.